4.Long-term Effects on LSCs: In a separate patient-derived xenograft (PDX) model focused on LSCs, second transplanted mice from T cells and BIF002 treated group showed no detectable leukemia cells in their blood and surv...
Hemebase is an interactive, web-based tool to browse, compare, and visualize models and patients from the largest functional-genomic knowledgebase to date, including over 600 AML patients, over 1000 DLBCL patients, over 60 AML/DLBCL cell lines and sources of PDX mouse models (Crown/Champion)....
Figure 2. Signal increase curve in OCI-AML-3-Luc xenograft model (n=4) Figure 3. Body weight change of OCI-AML-3-Luc xenograft model (n=4) Figure 4. Survival curve of OCI-AML-3-Luc xenograft mouse model (n=4) Figure 5. Bioluminescence imaging of OCI-AML-3-Luc xenograft mouse mod...
Interestingly, active oxidative phosphorylation, but not quiescent dormancy, was recently shown to be a dominant feature in cytarabine-treated AML cells in PDX mouse models [6]. The lack of molecular profiles of LSCs in these mice may be due to the following reasons that may not be mutually ...
Mouse model studies employing patient pre-chemotherapy samples have proposed that leukemia stem cells (LSCs) with self-renewal properties can preferentially survive chemotherapy [4]. Nevertheless, this prediction is mainly based on their inherent dormancy and has not been demonstrated in post-treatment ...
(I) Engraftment of PDX#3 in NSG-SGM3 mice on d-18 was followed by treatment with 5 × 105 CAR/CCRpos T cells on d0. Also see Figure S6. Humanized AML mouse model to assess ADCLEC.syn1 efficacy and HSPC toxicity We next evaluated the on-target/off-tumor activity of ADCLEC.syn1...
The therapeutic potential of AB8939 has been demonstrated through a series of preclinical experiments [2–4].Invivodata from a highly resistant Ara-C patient derived xenograft (PDX) mouse model showed that AB8939, ...
Mouse xenograft model NOD/SCID mice were injected with 200 000 cells subcutaneously and treated, from the subsequent day after injection, with twice weekly intravenous 12 mg/kg gedatolisib or vehicle (5% (278 mM) dextrose in water, 0.3% lactic acid pH 3.5) for 25 days. Experiment was ...
[127,128,129], whose effectiveness against AML remains unreported. One study reports the discovery of a class of DNMT1-selective inhibitors and their improved tolerance in vivo compared to decitabine, yielding a better mouse model of AML [130]. A later study identified two structurally related ...
Moreover, with the genetic loss of function mouse model, we found that loss of Gpr68 did not impair the survival of mouse HSPC [24]. Consistently, depletion of GPR68 did not impair the survival of human HSPC. These results implied that GPR68 was required for AML cell survival but ...